The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Caris Life Sciences Inc (NASDAQ: CAI) closed at $26.7 in the last session, down -0.22% from day before closing price of $26.76. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 2.26 million shares were traded. CAI stock price reached its highest trading level at $26.88 during the session, while it also had its lowest trading level at $25.532.
Ratios:
We take a closer look at CAI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.36 and its Current Ratio is at 9.93. In the meantime, Its Debt-to-Equity ratio is 0.89 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on December 02, 2025, initiated with a Hold rating and assigned the stock a target price of $28.
On July 14, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.TD Cowen initiated its Buy rating on July 14, 2025, with a $32 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when Power Luke Thomas sold 62,250 shares for $26.58 per share. The transaction valued at 1,654,461 led to the insider holds 99,571 shares of the business.
LUKE POWER bought 62,250 shares of CAI for $1,686,975 on Dec 11 ’25. On Nov 07 ’25, another insider, Denton John Russel, who serves as the insider of the company, bought 4,184 shares for $24.09 each. As a result, the insider paid 100,793 and bolstered with 9,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 7533322752 and an Enterprise Value of 7204568064. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.61 while its Price-to-Book (P/B) ratio in mrq is 15.75. Its current Enterprise Value per Revenue stands at 11.1 whereas that against EBITDA is -136.053.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $42.50, while it has fallen to a 52-week low of $22.86. The 50-Day Moving Average of the stock is -4.97%, while the 200-Day Moving Average is calculated to be -11.08%.
Shares Statistics:
According to the various share statistics, CAI traded on average about 1.45M shares per day over the past 3-months and 3426280 shares per day over the past 10 days. A total of 282.10M shares are outstanding, with a floating share count of 115.32M. Insiders hold about 59.13% of the company’s shares, while institutions hold 37.37% stake in the company. Shares short for CAI as of 1764288000 were 6840155 with a Short Ratio of 4.70, compared to 1761868800 on 4190099. Therefore, it implies a Short% of Shares Outstanding of 6840155 and a Short% of Float of 4.7.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.66 and -$0.73 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $0.19, with 4.0 analysts recommending between $0.46 and -$0.05.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $204.64M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.7M.
Based on 9 analysts’ estimates, the company’s revenue will be $976.03M in the next fiscal year. The high estimate is $1.02B and the low estimate is $932.2M.
